Alzamend Neuro (ALZN) vs KALA BIO (KALA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alzamend Neuro is the larger company by market cap ($6.5 million vs $5.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | KALA |
|---|---|---|
| Share price | $1.34 | $0.2939 |
| Market cap | $6.47M | $5.68M |
| 1-day change | 0.00% | -0.91% |
| EPS (TTM) | $-2.33 | $-10.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $95.50 |
| 52-week low | $0.84 | $0.286 |
| Distance from 52-week high | -50.00% | -99.69% |
| Analyst consensus | none | — |
| Avg. price target upside | +1840.30% | — |
| Average volume | 88.54K | 1.48M |
| Shares outstanding | 4.83M | 19.34M |
| Employees | 4 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ALZN vs KALA FAQ
Which is bigger, Alzamend Neuro or KALA BIO?
Alzamend Neuro (ALZN) is larger, with a market capitalization of $6.47M compared with $5.68M for KALA BIO (KALA).
Are Alzamend Neuro and KALA BIO in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.